Combination therapy with an anti-hyaluronan agent and therapeutic agent
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-047/48
A61K-031/56
A61K-031/7068
A61K-031/337
A61K-038/47
A61K-031/37
A61K-031/42
A61K-031/573
A61K-031/706
A61K-031/7076
A61K-031/7088
C12N-009/06
C12N-009/26
A61K-045/06
A61K-009/00
A61K-047/60
A61K-047/56
A61K-047/64
출원번호
US-0815804
(2013-03-15)
등록번호
US-9913822
(2018-03-13)
발명자
/ 주소
Maneval, Daniel C.
Shepard, H. Michael
Thompson, Curtis B.
출원인 / 주소
Halozyme, Inc.
대리인 / 주소
Dentons US LLP
인용정보
피인용 횟수 :
0인용 특허 :
100
초록▼
Provided herein is combination therapy containing an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating c
Provided herein is combination therapy containing an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.
대표청구항▼
1. A combination, comprising: a) a composition comprising a soluble PEGylated PH20 hyaluronidase; wherein the PH20 hyaluronidase comprises an amino acid sequence that has at least 95% sequence identity to the sequence set forth in SEQ ID NO: 4; andb) a composition comprising a tumor-targeted taxane
1. A combination, comprising: a) a composition comprising a soluble PEGylated PH20 hyaluronidase; wherein the PH20 hyaluronidase comprises an amino acid sequence that has at least 95% sequence identity to the sequence set forth in SEQ ID NO: 4; andb) a composition comprising a tumor-targeted taxane that is nab-paclitaxel or nab-docetaxel. 2. The combination of claim 1, wherein: the compositions are formulated for direct administration;the concentration of hyaluronidase is sufficient to degrade tumor-associated hyaluronan; andthe concentration of tumor-targeted taxane is sufficient to achieve intratumoral delivery of the taxane. 3. The combination of claim 1, wherein the concentration of tumor-targeted taxane is sufficient to reduce intratumoral nucleoside deaminase protein levels or protein activity compared to the levels or activity of the nucleoside deaminase in the absence of the intratumoral taxane formulation. 4. The combination of claim 1, wherein the hyaluronidase and tumor-targeted taxane are co-formulated for administration in a single composition. 5. The combination of claim 1, further comprising a composition comprising a nucleoside analog, or prodrug thereof, that is a chemotherapeutic agent. 6. The combination of claim 5, wherein: the composition is formulated for direct administration; andthe concentration of nucleoside analog is sufficient to achieve intratumoral delivery. 7. The combination of claim 5, wherein the nucleoside analog or prodrug thereof is provided separately from the hyaluronidase and tumor-targeted taxane. 8. The combination of claim 5, wherein the nucleoside analog or prodrug thereof is co-formulated with one or both of the hyaluronidase and the tumor-targeted taxane. 9. The combination of claim 1, wherein the compositions are formulated for multiple dosage administration. 10. The combination of claim 1, wherein the compositions are formulated for single dosage administration. 11. The combination of claim 1, wherein: the hyaluronidase composition contains between or about between 0.5 μg to 50 mg hyaluronidase conjugated to a polymer; orthe hyaluronidase composition contains between or about between 150 Units (U) to 60,000 U hyaluronidase conjugated to a polymer. 12. The combination of claim 11, wherein the volume of the composition containing the hyaluronidase is between or about between 0.5 mL to 100 mL. 13. The combination of claim 1, wherein the hyaluronidase is a PH20 that is a truncated human PH20, a bovine PH20 or an ovine PH20. 14. The combination of claim 1, wherein: the hyaluronidase is a truncated human PH20;the hyaluronidase is neutral active and soluble; andthe truncated PH20 comprises an amino acid sequence that contains a contiguous amino acid sequence, including at least amino acids 36-464 of SEQ ID NO:1 and terminates at a residue selected from 477, 478, 479, 480, 481, 482 or 483, or consists of an amino acid sequence that has at least 98% sequence identity to the polypeptide of SEQ ID NO:48. 15. The combination of claim 1, wherein the PH20 comprises the amino acid sequence set forth in any of SEQ ID NOS: 4-9, 47, 48, 150-170, 183-189, or an amino acid sequence that has at least 98% sequence identity to an amino acid sequence set forth in any of SEQ ID NOS: 4-9, 47, 48, 150-170, 183-189 and retains hyaluronidase activity. 16. The combination of claim 1, wherein: the tumor-targeted taxane is formulated as a delivery vehicle selected from among a micelle, nanoparticle, microsphere, liposomes or hydrogel; andthe delivery vehicle is linked directly or indirectly to a tumor targeting moiety. 17. The combination of claim 1, wherein the tumor-targeted taxane composition contains a concentration of tumor-targeted taxane that is between or about between 0.01 mg taxane/mL to 100 mg/mL. 18. The combination of claim 17, wherein the volume of the composition comprising a tumor targeted taxane is between or about between 0.5 mL to 100 mL. 19. The combination of claim 5, wherein the nucleoside analog is a purine or pyrimidine analog or derivatives thereof. 20. The combination of claim 19, wherein the nucleoside analog is selected from among fluoropyrimidine 5-fluorouracil, 5-fluoro-2′-deoxycytidine, cytarabine, gemcitabine, troxacitabine, decitabine, Azacytidine, pseudoisocytidine, Zebularine, Ancitabine, Fazarabine, 6-azacytidine, capecitabine, N4-octadecyl-cytarabine, elaidic acid cytarabine, fludarabine, cladribine, clofarabine, nelarabine, forodesine, and pentostatin, or derivatives thereof. 21. The combination of claim 5, wherein the nucleoside analog composition comprises a concentration of nucleoside analog that is between or about between 1 mg nucleoside analog/ml to 500 mg/ml, 5 mg/mL to 100 mg/ml, 10 mg/mL to 50 mg/mL, 25 mg/mL to 200 mg/mL or 20 mg/mL to 100 mg/mL. 22. The combination of claim 21, wherein the volume of the composition comprising a nucleoside analog is between or about between 0.5 mL to 1000 mL. 23. The combination of claim 1, wherein the composition(s) is (are) formulated for administration orally, intravenously (IV), subcutaneously, intramuscularly, intra-tumorally, intradermally, topically, transdermally, rectally, intrathecally or sub-epidermally. 24. The combination of claim 1, wherein the PEGylation moiety is selected from among polyethylene glycols (PEGs) and methoxypolyethylene glycols (mPEGs). 25. The combination of claim 1, wherein the PEGylation moiety is selected from among methoxypolyethylene glycols (mPEGs). 26. The combination of claim 1, wherein the PEGylation moiety is a PEG, and the PEG is a branched or linear PEG. 27. The combination of claim 1, wherein the PEGylation moiety is produced by reaction with methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (5 kDa); methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl butanoate (mPEG-SBA) (30 kDa); methoxy-poly(ethylene glycol)-succinimidyl α-methylbutanoate (mPEG-SMB) (20 kDa); methoxy-poly(ethylene glycol)-succinimidyl α-methylbutanoate (mPEG-SMB) (30 kDa); methoxy-poly(ethylene glycol)-butyraldehyde (mPEG-butyraldehyde) (30 kDa), methoxy -poly(ethylene glycol)-succinimidyl propionate (mPEG-SPA) (20 kDa); methoxy -poly(ethylene glycol)-succinimidyl propionate (mPEG-SPA) (30 kDa); (methoxy -poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (10 kDa branched); methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (20 kDa branched); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) 40 kDa branched); (methoxy-poly(ethylene glycol)) 2-N-hydroxysuccinimide ester (mPEG2-NHS) (60 kDa branched); biotin-poly(ethylene glycol)-N-hydroxysuccinimide ester (biotin-PEG-NHS) (5 kDa biotinylated); poly(ethylene glycol)-p-nitrophenyl carbonate (PEG-p-nitrophenyl-carbonate) (30 kDa); or poly(ethylene glycol)-priopionaldehyde (PEG-propionaldehyde) (30 kDa). 28. The combination of claim 1 that is packaged as a kit and optionally includes instructions for use. 29. The combination of claim 5, wherein the soluble PH20 hyaluronidase consists of the amino acid sequence set forth in any of SEQ ID NOS: 4-9, 47, 48, 150-170, 183-189, or an amino acid sequence that exhibits at least 98% sequence identity to an amino acid sequence set forth in SEQ ID NO: 4. 30. The combination of claim 5, wherein the PEGylation moiety is a polyethylene glycol (PEG). 31. The combination of claim 5, wherein the nucleoside analog is gemcitabine or a derivative thereof. 32. The combination of claim 1, wherein the hyaluronidase composition contains between or about between 50 Units hyaluronidase activity (U)/ml to 15,000 U/mL. 33. The combination of claim 5, wherein the nucleoside analog is a substrate for a nucleoside deaminase, and the nucleoside deaminase is adenosine deaminase or cytidine deaminase. 34. The combination of claim 1, comprising: a) a composition comprising PEGylated soluble PH20 hyaluronidase; andb) a composition comprising a tumor-targeted taxane that is nab-paclitaxel. 35. The combination of claim 1, wherein: the soluble PH20 consists of an amino acid sequence that has 98% sequence identity to residues 36-483 of SEQ ID NO:1; andthe albumin-conjugated taxane is Nab-paclitaxel.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (100)
Wildfeuer Marvin E. (Lafayette IN), 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides.
Kjell Douglas P. (West Lafayette IN), Catalytic stereoselective glycosylation process for preparing 2′-deoxy-2′,2′-difluoronucleosides and 2′-deoxy-2′-fl.
Pita Joe W. (880 NE. 75th St. Miami FL 33138) Mershon Scott (1009 Meridian Ave. ; #16 Miami Beach FL 33139) Muskat Michael A. (1230 95th St. Bay Harbor FL 33154), Chemiluminescent reactive vessel.
Studier F. William (Stony Brook NY) Davanloo Parichehre (Basel NY CHX) Rosenberg Alan H. (Setauket NY) Moffatt Barbara A. (East Lansing MI) Dunn John J. (Bellport NY), Cloning and expression of the gene for bacteriophage T7 RNA polymerase.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Marshall Lucia G. I. (St. Charles MO) Patel Kanaiyalal R. (St. Louis MO) Roufa Dikla G. (St. Louis MO), Controlled release formulations of trophic factors in ganglioside-lipsome vehicle.
Stella Valentino J. (Lawrence KS) Mathew Abraham E. (Lenexa KS), Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof.
Bally Marcel B.,CAX ; Cullis Pieter R.,CAX ; Hope Michael J.,CAX ; Madden Thomas D.,CAX ; Mayer Lawrence D.,CAX, Encapsulation of antineoplastic agents in liposomes.
Nho, Kwang; Chang-min, Hyun; Lee, Jung-Hun; Kim, In-Kyung; Pak, Young-Kyoung, Hexa-arm polyethylene glycol and its derivatives and the methods of preparation thereof.
Frost, Gregory I.; Kundu, Anirban; Bookbinder, Louis H., Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof.
Stern Robert ; Frost Gregory I. ; Csoka Anthony ; Wong Tim M., Hybridoma cell lines producing monoclonal antibodies that bind to human plasma hyaluronidase.
Shaukat Ali ; J. Craig Franklin ; Imran Ahmad ; Eric Mayhew ; Soumendu Bhattacharya ; Gil Koehane ; Andrew S. Janoff, Hydrolysis-promoting hydrophobic taxane derivatives.
Shepard, H. Michael; Li, Xiaoming; Thompson, Curtis, Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods.
Harris J. Milton (Huntsville AL), Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for m.
Mohr Judy M. (Menlo Park CA) Baker Richard W. (Palo Alto CA) Nakaji Lisa A. (San Jose CA), Liquid reservoir transdermal patch for the administration of ketorolac.
Bartley Timothy D. ; Bogenberger Jakob M. ; Bosselman Robert A. ; Hunt Pamela ; Kinstler Olaf B. ; Samal Babru B., Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation.
Desai Neil P. (Los Angeles CA) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP).
Bartley Timothy D. ; Bogenberger Jakob M. ; Bosselman Robert A. ; Hunt Pamela ; Kinstler Olaf B. ; Samal Babru B., Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation.
Harris J. Milton ; Veronese Francesco Maria,ITX ; Caliceti Paolo,ITX ; Schiavon Oddone,ITX, Multiarmed, monofunctional, polymer for coupling to molecules and surfaces.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Santus Giancarlo (Milan ITX) Bilato Ettore (Padua ITX) Lazzarini Gabriele (Pero ITX), Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension.
Le Grazie Cristina (Milan ITX), Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutic.
Harris J. Milton (Huntsville AL) Kozlowski Antoni (Huntsville AL), Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives t.
Desai, Neil P.; Tao, Chunlin; Yang, Andrew; Louie, Leslie; Yao, Zhiwen; Soon-Shiong, Patrick; Magdassi, Shlomo, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
Bookbinder, Louis H.; Kundu, Anirbau; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
Bookbinder, Louis; Kundu, Anirban; Frost, Gregory I., Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof.
Chou Ta-Sen (Indianapolis IN) Poteet Laurie M. (Zionsville IN) Kjell Douglas P. (West Lafayette IN), Stereoselective glycosylation process for preparing 2\-Deoxy-2\, 2\-difluoronucleosides and 2\-deoxy-2\-fluoronucleoside.
Haugwitz Rudiger D. (Bethesda MD) Zalkow Leon (Atlanta GA) Glinski Jan (Ridgefield CT) Suffness Mathew (Silver Spring MD) Deutsch Howard M. (Atlanta GA) Narayanan Venkatachala (Gaithersburg MD), Water soluble, antineoplastic derivatives of taxol.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.